Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.81 |
| ▸ | NT5E | P21589 | 1/20 | 0.76 |
| ▸ | KRAS | P01116 | 2/20 | 0.76 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.75 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.71 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.71 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.71 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.68 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.65 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.65 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gtp SCHEMBL18271799 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL3333959 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL376140 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL18784960 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL376139 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL1304258 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL19691775 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL2593095 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL17367368 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL96708 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309447-A1 | METHODS AND KITS FOR PREPARING A SAMPLE COMPRISING ONE OR MORE RNA MOLECULES FOR SEQUENCING | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-09-19 | — | — | US | claimed |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | claimed |
| CN-121041304-B | Application of CCT018159 and nelarabine in preparation of acute leukemia drugs | HARBIN MEDICAL UNIVERSITY (CN) | 2026-05-29 | — | — | CN | disclosed |
| CN-121041304-A | Application of CCT018159 and nelarabine in preparation of acute leukemia drugs | 哈尔滨医科大学 | 2025-12-02 | — | — | CN | disclosed |
| US-20240309447-A1 | METHODS AND KITS FOR PREPARING A SAMPLE COMPRISING ONE OR MORE RNA MOLECULES FOR SEQUENCING | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-09-19 | — | — | US | disclosed |
| WO-2006114065-A2 | USE OF COMPOUNDS TO INHIBIT NEOPLASIA | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY A CADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2006-11-02 | — | — | WO | disclosed |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-20 | — | — | US | disclosed |
| WO-2004012769-A1 | THERAPEUTIC INHIBITIONOF PROTEIN KINASES IN CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040096436-A1 | Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a | IMPDH1, IMPDH2, DCK | TGM2 1994/4885NT5E 576/4885KRAS 1035/4885 |
| US-20040127435-A1 | Uses for inhibitors of inosine monophosphate dehydrogenase | IMPDH1, IMPDH2, IMPA1 | TGM2 880/4885NT5E 57/4885KRAS 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.